Investments & Savings
Investments and Savings
Explore investments & savings
Explore investments & savings
Investments
Smart Cash
All Weather
Global Stocks
Global Bonds
Personalised investments
Custom Index
Thematics
Coming soon
Advanced opportunities
Private Equity
Bitcoin ETN
VCTs
Coming soon
Savings
Multi Shield
Easy Access
Fixed Term
Accounts
Stocks & Shares ISA
Services
Borrowing
Learn
Stories
About Us
Get started
Get started
Our weekly
Market Pulses
Most recent
December 5, 2025
Anthropic considers possible 2026 IPO, big banks take on crypto, and Starmer rejects joining EU customs union.
Read the Pulse
Most recent
November 28, 2025
Reeves hikes taxes in autumn budget, Alphabet stages AI comeback, and the ECB flags market risks
Read the Pulse
Most recent
November 21, 2025
Europe debates the digital euro, UK inflation dips in October, and UK deposit protection limit climbs.
Read the Pulse
Most recent
November 13, 2025
Starmer faces leadership challenge, banks push back at private credit, and companies become safer than sovereigns
Read the Pulse
Most recent
November 6, 2025
Reeves teases tax hikes, US tariffs face court test, and Amazon sues Perplexity
Read the Pulse
Most recent
October 31, 2025
US and China cool trade tensions, Nvidia eclipses $5 trillion valuation, and UK mortgage approvals jump
Read the Pulse
Most recent
October 24, 2025
AWS outage highlights cloud concentration, Japan’s widowmaker trade pays off, and UK inflation stabilises in September
Read the Pulse
Most recent
October 17, 2025
China triggers global pushback on rare earths, FCA opens door to crypto assets, and Wall Street conflicted over economic pain
Read the Pulse
Most recent
October 10, 2025
US demands threaten EU trade deal, gold reaches highest price in history, and a data error works in Reeves’ favour
Read the Pulse
Most recent
October 3, 2025
UK inflation runs hot, US pushes for bank rule changes, and the yuan closes in on the pound
Read the Pulse
Most recent
September 26, 2025
Nvidia’s $100 billion OpenAI deal, Tether’s $500 billion valuation, and the political risks facing pharma investors
Read the Pulse
Previous
Load more
3 / 15